Medical/Pharmaceuticals

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153 Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for t...

2025-10-23 04:00 2269

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star inChina's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a$250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone ...

2025-10-22 23:39 2457

CathWorks Announces Key Events for TCT 2025

The CathWorks FFRangio® System to be Center Stage, Featured in Multiple Scientific Sessions, Live Cases and a Primetime Academic Satellite Program NEWPORT BEACH, Calif., Oct. 22, 2025 /PRNewswire/ -- CathWorks, a global leader in digital health innovations, announced today the schedule of key ev...

2025-10-22 22:05 1751

Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating th...

2025-10-22 18:00 2815

HMI Medical Expands Advanced Imaging Services to Strengthen Diagnostic Capabilities in Singapore

* HMI Radiology (Novena) will deliver a full suite of diagnostic imaging services to aid in early detection and proactive health management in the community * Integration of Siemens Healthineers high-resolution imaging systems and AI-enhanced workflows drives patient-centric innovation and br...

2025-10-22 15:35 2488

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

* Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors * Dr. Fain brings over 35 years of strategic and start-up expertise * Extensive experience in the Cardiovascular space particularly in active implants * Led multiple successful financings and exits on both the strategic...

2025-10-22 15:00 1506

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's propriet...

2025-10-22 14:00 3288

ACROBiosystems and Partners Conclude OrganoAsia 2025

ACROBiosystems and Partners Conclude OrganoAsia 2025 - Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystem...

2025-10-22 11:03 5460

ACROBiosystems and Partners Conclude OrganoAsia 2025

In the news release, ACROBiosystems and Partners Conclude OrganoAsia 2025, issued10-Oct-2025 by ACROBiosystems Group over PR Newswire, "Tokyo University of Science" in the paragraph starting with "The conference gathered leading specialists such as..." should read "Institute of Science Tokyo"....

2025-10-22 11:01 4792

HKSH Medical Group to Host Hong Kong's First Asia-Oceania Particle Therapy Co-operative Group Conference

Best Practice by World-class Experts in Proton Therapy Transforming Precision Cancer Management HONG KONG, Oct. 21, 2025 /PRNewswire/ -- HKSH Medical Group (HKSH) introduced Hong Kong's only and the Greater Bay Area's first proton therapy system in 2023, after two decades of planning and prepara...

2025-10-21 16:02 3954

Getinge Interim Report July-September 2025: High organic sales growth and stronger margins despite geopolitical headwinds

GOTHENBURG, Sweden, Oct. 21, 2025 /PRNewswire/ -- "We demonstrated strength in the third quarter with significant organic growth, improved profitability and cash flow despite impacts from tariffs and negative currency effects," says Mattias Perjos, President & CEO, Getinge. The medtech company's ...

2025-10-21 14:45 2009

Abbott and BIG CARiNG Group Launch Nationwide Influenza Awareness Program to Strengthen Public Health Response Through Early Intervention

KUALA LUMPUR, Malaysia, Oct. 21, 2025 /PRNewswire/ -- Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one ofMalaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness acrossMalaysia. The Influenza Awareness Program, running ...

2025-10-21 13:12 2446

LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today

JOHNSON CITY, Tenn., Oct. 21, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, will be featured on the season 9 finale of the innovation-focused TV series, Tomorrow's World Today. Premiering on Science Channel on November 8,...

2025-10-21 01:11 1818

TraceLink Recognized on Fast Company's Next Big Things in Tech List

The annual list honors groundbreaking advancements redefining the way we work and live BOSTON, Oct. 20, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced its inclusion in Fast Company'sNext Big Thing...

2025-10-20 23:59 1841

BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission

PRAGUE, Oct. 20, 2025 /PRNewswire/ -- BTL, a global leader in medical technologies, proudly announces that its flagship device, EMSCULPT NEO, played a key role in astronaut preparation ahead of a historic spaceflight. As a result of the cooperation between BTL Hungary and HUNOR (Hungarian To Orbi...

2025-10-20 20:09 2728

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...

2025-10-20 17:06 2248

ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016)...

2025-10-20 14:58 2721

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global a...

2025-10-20 14:00 2413

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor rece...

2025-10-20 13:59 2320

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrou...

2025-10-20 13:21 1975
1 ... 67686970717273 ... 381

Week's Top Stories